Physicians at Holy Cross Health in Fort Lauderdale are leading several heart-related trials and studies. As a leader in clinical cardiac research, Holy Cross Health is continuing to expand efforts in offering innovative research studies to ensure the best possible long-term outcomes for patients in the community.
Among the heart studies currently underway are:
- evaluating the effect of in-hospital initiation of Dapagliflozin on clinical outcomes in patients who have been stabilized during hospitalization for Acute HF;
- collecting sensor and heart failure event data that will be used to develop and test new diagnostic features for the insertable cardiac monitor ICM systems;
- evaluating the efficacy and safety of AZD4831 in participants with heart failure with left ventricular ejection fraction;
- studying the safety and effectiveness of cardiac contractility modulation therapy in subjects with symptomatic heart failure;
- evaluating the efficacy and safety of the sGC Stimulator Vericiguat/MK-1242 in adults with stable heart failure with reduced ejection fraction;
- Acute ACS to investigate the efficacy and safety of CSL112 in subjects with Acute Coronary Syndrome;
- Recent ACS to investigate post-discharge care pathway for patients with a recent acute coronary syndrome who have elevated LDL-C despite being on maximally tolerated statin therapy following an ACS will be randomized to receive one of our new LDL-C lowering therapies or usual care
- Non interventional trial: the number of recurrent HF readmissions, with a monitoring period and time frame of 12 months, to determine if HEMOTAG and symptom guided treatment during a follow-up period results in decreased rate of heart failure re-hospitalizations.
- Pfizer C3651101 to study of the effects of Ponsegromabon Health Related quality of life and safety in patients with heart failure.
- SEGA trial, Neuro/Cardio, sedation vs. general anesthesia for endovascular therapy in acute ischemic stroke.
“We have always been on the leading-edge of technology and providing excellent care,” said Holy Cross Health President and CEO Mark Doyle. “We are continually providing increased access to studies and trials that will lead to positive outcomes for patients.”
Holy Cross Health has also been named a 2022-2023 High Performing hospital by U.S. News & World Report for eight conditions, including Heart Attack and Heart Failure, in recognition of care that was significantly better than the national average, as measured by factors such as patient outcomes.
Early detection of life-threatening heart disorders is possible through the use of Echocardiography procedures. Holy Cross is accredited in Echocardiography in the areas of Adult Transthoracic by the Intersocietal Accreditation Commission, which is only granted to facilities that provide quality patient care, in compliance with national standards through a comprehensive application process including detailed case study review.
Learn more at HolyCrossHeart.com
